Science Will Win: Recent Episodes
Pfizer
Science Will Win explores the fascinating science, policy, and humanity which is shaping the future of healthcare and transforming patients’ lives for the better.
Hosted by Adam Rutherford, geneticist and Honorary Fellow at University College London, our first miniseries takes listeners on a journey behind the science of gene therapy; the next generation of medicines bringing new possibilities for patients living with rare genetic diseases.
At a time when innovative science is achieving the seemingly impossible, we’ll look at gene therapy from every angle, speaking to scientists and experts on the forefront of medical research, as well as the patients and families who are holding new hope in the life-changing potential of gene therapy.
Cancer research is moving faster than ever—but too many patients never feel the impact of that progress. Artificial Intelligence (AI) is emerging as one tool that could help change that.
In the Season 6 finale of Science Will Win, Dr. Raven Baxter follows the human journey behind AI in oncology—from the moment of diagnosis to the real‑world barriers that determine access to care.
Along the way, we explore how thoughtfully designed artificial intelligence is reshaping trial design, enrollment, eligibility, and access—helping patients regain agency and bridging the gap between scientific breakthroughs and real‑world cancer care.
As the season concludes, one thing is clear: progress matters most when it reaches the people who need it.
Featured guests:
– Dr. Lionel Kankeu Fonkoua, Medical Oncologist and Translational Researcher, Mayo Clinic
– Jeff Legos, Chief Oncology Officer, Pfizer
– Dr. Ravi Parikh, Medical Oncologist; Director, Human‑Algorithm Collaboration Lab
– Maya R. Said, Founder and CEO, Outcomes4Me
Dive into the episode here:
00:00 – Past episodes introduce us to an emerging tech advancement
04:16 – What is a clinical trial?
07:35 – AI accelerating the pace of oncology
12:42 – Clinical trials and AI: How can it help?
16:17 – A gap between innovation and patient access
19:16 – Maya's story
23:47 – Clinical trials for AI tools
27:54 – Conclusion: building pathways alongside scientific innovation
Check out our YouTube channel (@Pfizer) to watch full interviews between Raven & some of the patients featured.
Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time.
*The content in this episode is for informational purposes only and does not provide medical advice. Pfizer does not endorse or sponsor third‑party tools referenced. Patients should not use the tools described as a replacement for discussions with a healthcare provider. Patients should consult their healthcare provider regarding medical decisions.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What comes after a cancer diagnosis and treatment?
In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most important, and often overlooked, chapters for cancer patients: survivorship. As five-year survival rates climb to 70%, more people than ever are living with and beyond cancer. But longer survival brings its own complex challenges, and our care systems are still catching up.
You'll hear from experts and advocates working at the intersection of medicine, policy, and community. We’ll discuss what it really takes to support people through this transition — when the clinical benchmarks have passed and it’s time to go back to “normal life”.
From patient care plans and workplace disclosure to mental health, this episode makes one thing clear: survivorship demands dignity, support, and a whole new kind of care.
Featured guests:
– Tina Deignan, Commercial President, Pfizer Oncology
– Shelley Fuld Nasso, CEO, Cancer Nation
– Rebecca Nellis, Executive Director, Cancer and Careers
– Bob Riter, Breast Cancer Patient & Advocate
Dive into the episode here:
00:00 – The ongoing battle with cancer
03:43 – Rethinking survivorship
05:32 – The five-year survival myth
07:00 – The history of the term "survivor"
09:36 – Bob’s journey with breast cancer
11:38 – Lost in transition and survivorship care plans
14:25 – The intersection of cancer and work
18:49 – Rethinking how work gets done
20:00 – Disclosure and improving company culture
20:59 – The swivel technique
23:19 – Controlling your narrative
25:11 – Standardizing long-term survivorship care through policy
27:08 – Lack of access to care leads to disparities in survival rates
29:48 – Bob's second journey with cancer
32:21 – Takeaways and peek into our final episode
Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Bob Riter on his cancer journey.
Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What women carry through cancer is more than a diagnosis.
In our third episode of this miniseries, Dr. Raven Baxter explores how generations of women turned silence into advocacy and fear into progress, reshaping the perceptions and discussions around cancer over time. Through history, science, and a powerful story from Katrina M. Johnson — a woman who has lived through multiple breast cancer diagnoses and now advocates for others — the episode highlights how women continue to drive change in how cancer is understood, treated, and lived with.
Featured guests:
– Dr. Isaac Chan, Physician‑scientist and Assistant Professor, Department of Internal Medicine, University of Texas Southwestern
– Kirsten Gardner, Director of Medical Humanities, University of Texas at San Antonio; Author
– Katrina M. Johnson, Breast Cancer Patient; Director of Advocacy and Professional Relations, Pfizer Oncology
Dive into the episode here:
00:00 – The start of three cancer diagnoses
02:06 – The history of breast cancer awareness campaigns
09:27 – How the mastectomy has changed
12:59 – Evolving research in breast cancer
15:10 – Breast cancer impacting body image and sexuality
19:29 – Emerging therapies to address breast cancer
21:18 – Addressing the BRCA gene today
23:30 – Breast cancer advocacy then and now
26:08 – Katrina's takeaways about her breast cancer story
Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Katrina M. Johnson on her breast cancer journey.
Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What if the key to treating cancer was hiding in plain sight – written into its DNA? In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most exciting breakthroughs in cancer care today: the discovery of biomarkers. These tiny molecular signals are helping doctors understand what’s really driving an individual person’s cancer – and opening the door to treatments that can dramatically change patient outcomes.
You’ll hear powerful stories from people whose cancers were traced back to a specific biomarker, alongside experts who break down what biomarker testing is, how it works, and why it’s transforming the way we think about cancer treatment.
Biomarkers are showing us that when we understand cancer at its molecular level, a disease that once felt like an unsolvable mystery starts to come into focus.
Featured guests:
– Dr. Ross Camidge, Director of Thoracic Oncology, University of Colorado
– Kelly Huffman, Lung Cancer Patient and Retail Account Manager, Pfizer
– Karin Tollefson, Chief Oncology Medical Officer, Pfizer
Dive into the episode here:
00:00 – An oncologist’s diagnosis introduces the world of biomarker
03:10 – Defining biomarkers and its history
06:24 – Discovery of the first lung cancer biomarker
08:39 – The start Kelly’s lung cancer journey
16:00 – Biomarkers: how do you test for them?
19:11– Discovery of ALK biomarker shift’s Kelly’s story
22:34 – Landscape of targeted therapy and lung cancer today
25:24 – Moving forward with targeted treatments and conclusion
Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Kelly Huffman on her lung cancer journey.
Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Why are more young adults getting cancer? That's one of the most pressing questions facing the scientific community today. Traditionally thought of as a disease that affects aging populations, recent data shows that cancer diagnoses for people under the age of 50 are increasing. To tackle this problem, it’ll take a global effort. In this episode you’ll hear from patients, oncologists, researchers and health care providers who are coming together to address this issue head on.
Featured guests:
– Dr. Marshall Anthony Jr., social scientist and colorectal cancer patient
– Dr. Johanna Bendell, Chief Development Officer of Oncology, Pfizer
– Dr. Yin Cao, molecular cancer epidemiologist; Cao Lab leader, Washington University
– Dr. Beatrice Dionigi, colorectal cancer surgeon; founder & co‑director, Early Onset Colon and Rectal Cancer Project, Columbia Research Cancer Center
– Dr. Susan Zhang, Global Development Lead, Pfizer Oncology
Dive into the episode here:
00:00 – A patient story reveals an alarming new trend
6:30 – The data behind the rise of early-onset cancer
10:39 – The global search for a cause
14:13 – The unique challenges facing young people with cancer
20:28 – Screening guidelines and what to expect from a colonoscopy
25:17 – The importance of early detection
27:59 – The conclusion of Marshall's cancer journey
30:23 – What's next, and closing thoughts
Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Dr. Marshall Anthony Jr. on his colorectal cancer journey.
Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Science Will Win is back for a new season! Dr. Raven Baxter, a molecular biologist also known as Raven the Science Maven, returns as our host to dive into the latest in oncology: The latest challenges, the latest research, the latest treatment approaches, and the latest sources of progress and optimism keeping researchers going. You’ll hear from leading doctors, cutting-edge scientists, insightful historians, and inspiring patients sharing powerful stories of resilience. Plus, for the first time, you can find full length video discussions led by Raven on Pfizer’s YouTube channel. Season 6 of Science Will Win is coming soon—subscribe to stay tuned in!
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In drug discovery and development, every part of the process matters. Scientists learn from every experiment and every observation. In fact, some of the most cutting-edge advancements in medicine are being dreamed up from findings uncovered in the past.
In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble dive deep into antibody drug conjugates, a groundbreaking modality that uses targeted antibody engineering to deliver potent chemotherapy directly to cancer-causing cells. They explore the complex ADC creation process and learn how ADCs are changing the standard of care for bladder cancer, from someone with a personal relationship to the disease.
Featured Guests:
– Renee Barron-Gores, Caregiver
– Phoenix Ho, Vice President, Oncology Early Clinical Development, Pfizer
– Sharsti Sandall, Executive Director, ADC Biology, Oncology Research Unit, Pfizer
Dive into the episode here:
1:16 - Old ideas yield new discoveries
3:01 - How do antibody drug conjugates work?
5:07 - The origins of ADCs
8:36 - ADCs allow for more targeted cancer treatment
10:44 - How are ADCs structured?
14:16 - How do scientists find the best ADC combinations?
18:27 - Developing oncology drugs
22:02 - ADCs and bladder cancer
24:28 - A caregiver’s perspective on cancer treatment
38:12 - Science Will Win
Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios.
Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer)
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Protein-protein interactions facilitate numerous bodily processes – everything from the basics of how our muscles contract to the more complex ways cancer can spread through the body. So, what if there was a way to alter some of these interactions? Or even create new ones?
In this episode, we’re diving into the fascinating field of molecular glues, a revolutionary modality on the precipice of changing the treatment landscape for certain cancers and potentially other diseases and conditions.
Featured Guests:
– Joyann Donaldson, Principal Scientist, Synthesis Group Lead, Pfizer
– Jennifer LaFontaine, Head of Oncology Medicinal Chemistry, Pfizer
– Neal Sach, Research Fellow, Pfizer
– Jillian Spangler, Associate Research Fellow, Pfizer
Dive into the episode here:
0:50 - A metaphor to explain molecular glues
2:36 - How do molecular glues work in the body?
5:57 - A new frontier for cancer treatment
13:05 - The history behind molecular glues
16:59 - How do scientists design molecular glues?
19:05 - A visit to Pfizer’s La Jolla labs
32:42 - How can molecular glues change the patient experience?
36:42 - Molecular glues beyond cancer treatment
Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios.
Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer)
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The next frontier of medicine is focused on highly targeted drug therapies that could expand the possibilities of individualized patient care. Today, scientists are working on a particular type of molecule that could harness multiple capabilities and treat inflammatory and autoimmune diseases in ways never done before.
In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble explore how the latest advancements in antibody engineering led to multispecific antibodies—powerhouse molecules that can do the jobs of multiple drugs in one. They learn all about what it takes to assemble these antibodies and the impact they could make on patients—with a patient.
Featured Guests:
– Emma Guttman, Chair of the Department of Dermatology, Icahn School of Medicine at Mount Sinai
– Amanda Lopez, Patient, Texas Ambassador for the National Eczema Association
– Laird Bloom, Senior Director of Biomedicine Design, Pfizer
– Thomas Wynn, Vice President of Discovery, Inflammation & Immunology, Pfizer
Dive into the episode here:
1:12 - A metaphor for multispecific antibodies
4:08 - How do multispecific antibodies work?
10:39 - The history behind multispecific antibodies
16:29 - How are multispecific antibody drugs are made?
22:58 - An eczema expert on the potential of multispecific antibodies
29:30 - Amanda Lopez's eczema story
40:14 - What's next, and closing thoughts
Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios.
Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer)
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Medical advancements don’t just spring up—they happen by building on decades of previous discoveries. Today, one of these advancements might be on the verge of another breakthrough. But what had to happen first for it to exist?
In this episode, co-hosts Dr. Raven Baxter and Dr. Ronald Gamble explore how a vaccine candidate for a deadly, once-mysterious bacterial disease came to be. The story takes them from one doctor’s groundbreaking connection in the 70s, all the way to a real lab where vaccines are being developed today.
Featured Guests:
– Carol Baker, Pediatric Infectious Disease Specialist
– Isis Kanevsky, Senior Director, Vaccines, Pfizer
– Ksenia Krylova, Senior Director, Vaccines, Pfizer
Dive into the episode here:
02:54 - Getting into the problem
05:11 - The basics of immunity and vaccine science
09:32 - What is a conjugate vaccine?
14:44 - Group B Strep: A case study
22:23 - Talking to a GBS pioneer
31:40 - A trip to the lab
43:08 - What's next, and closing thoughts
Season 5 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter and Dr. Ronald Gamble. It’s produced by Acast Creative Studios.
Check out our social media platforms to take a deeper look into the labs and stories we discuss during the episodes: Instagram (@pfizerinc), TikTok (@pfizer)
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Science Will Win is back for a new season, with new hosts and a new format. Now, science educators Dr. Raven Baxter a molecular biologist otherwise known as Raven, the Science Maven, and Dr. Ronald Gamble, a theoretical astrophysicist at NASA, are teaming up to explore four exciting medical technologies. These technologies are right on the cusp of a potentially groundbreaking moment, either unlocking our ability to tackle new diseases or allowing us to tackle old ones in ways we never could before. This journey takes our hosts through discussions with cutting edge researchers, stories of medical mysteries solved, and tours of real labs that are used every day in the quest to create new medicines. Tune in to the latest four-part season, coming soon!
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Over the last five years, the healthcare industry has witnessed an explosive surge in digital health services, revolutionizing the way we access medical care. Patients today are taking charge of their health journey by using different digital tools to stay on top of their preventative screenings, implement dietary and lifestyle changes, access mental health resources, and so much more. In this conversation, patient advocates and industry leaders from Noom, Thrive, and Pfizer, dive into the potential power of artificial intelligence and the anticipated transformation in personalized health plans. They share real-world examples that highlight how digital technologies are helping patients feel empowered and shape the future of healthcare.
Through this conversation you heard Lidia Fonseca reference Health Answers by Pfizer. In February 2025, the Pfizer team launched this new platform, powered by generative AI that provides clear, relevant answers to your health & wellness questions and helps you take action for yourself and your loved ones. To learn more, visit healthanswers.pfizer.com.
Moderator:
Stephanie Agresta, Managing Director, Ascendancy Events
Featured experts:
-Karin Bilich, Head of Content, Noom
-Lidia Fonseca, Chief Digital & Technology Officer, Pfizer
-MT Grant, SVP & GM, Thrive for Health
This episode was recorded live in Austin, TX on Monday, March 10, as part of Pfizer’s takeover of the South by Southwest podcasting lounge.
Please fill out our short survey so we can get to know our listeners better: pfizer.com/podcastsurvey
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
While cancer deaths in the United States have declined in recent years, some populations are being left behind—facing complicated challenges to accessing the care they need. Intervening at the earliest stages of disease onset is critical to cancer treatment success and to reducing the risk of recurrence. So how do we create a world where all people with cancer are quickly diagnosed and can live better, longer lives as science advances? In this conversation, patient advocates and healthcare leaders from Pfizer, the American Cancer Society, and the Healthcare Businesswomen’s Association, discuss the power of collaboration in the effort to “Outdo Cancer.”
Moderator
• Tyrone McClain, Senior Director, Public Affairs, Pfizer
Speakers
• Carmen White, U.S. & Global Oncology Health Equity Lead, Pfizer
• Pam Traxel, American Cancer Society, Cancer Action Network
• Mary Stutts, CEO, Healthcare Businesswomen's Association (HBA)
This episode was recorded live in Austin, TX on Monday, March 10, as part of Pfizer’s takeover of the South by Southwest podcasting lounge.
Please fill out our short survey so we can get to know our listeners better: pfizer.com/podcastsurvey
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Podcasting has become essential for communicating breakthroughs in science, offering an accessible and engaging platform to reach diverse audiences. This evolving medium fosters deeper connections by delivering trusted information in accessible and compelling ways. In this conversation, audio makers from Pfizer, Acast, and TED, discuss what it takes to stand out in the science podcast space, insights on strategy, and how they're working to shape the future of health communication.
Moderator
• Aaron Strout, Former CMO of Real Chemistry and Health Podcaster
Speakers
• Erica Santiago, Executive/Digital Communications & Podcast Strategy, Pfizer
• Veronika Taylor, SVP of Acast’s Creator Network
• Shoshana Ungerleider MD, Host and Producer of TED Health Podcast
This episode was recorded live in Austin, TX on Monday, March 10, as part of Pfizer’s takeover of the South by Southwest podcasting lounge.
Please fill out our short survey so we can get to know our listeners better: pfizer.com/podcastsurvey
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
So far in this season, we’ve explored how innovations throughout history have brought us to where we are now. We talked about how drug discovery changed from a serendipity-based to data-based endeavor. Then, we explored the powerful hardware and smart software required to accommodate big data. Now, the door to the future of AI in drug discovery is open. In our final episode, we’re looking toward the future, to understand where today’s advancements could potentially take us.
Featured Guests:
–Charlotte Allerton, Head of Preclinical and Translational Sciences at Pfizer
–Daniel Ziemek, Vice President of Integrative Biology and Systems Immunology at Pfizer
–Enoch Huang, Head of Machine Learning and Computational Sciences at Pfizer
–Dr. Raza Ali, group leader at the University of Cambridge Cancer Research UK Institute, pathologist
Season 4 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
With a trove of data and powerful hardware to process it, software is the last element of our artificial intelligence story. In this episode, host Jeremiah Owyang and expert guests explore the history of advancement behind the software that powers AI today. They delve into the creation of neural networks at the heart of this technology and how scientists are partnering with AI to revolutionize the complex process of drug development and discovery.
Featured Guests:
–Beth Cimini, Associate Director for Bio image Analysis at the Broad Institute in Cambridge, Massachusetts
–Charlotte Allerton, Head of Preclinical and Translational Sciences at Pfizer
–Daniel Ziemek, Vice President of Integrative Biology and Systems Immunology at Pfizer
–Enoch Huang, Head of Machine Learning and Computational Sciences at Pfizer
Season 4 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Last episode discussed data and how crucial large swaths of data are in assisting drug development. But more data requires a lot of storage – and that’s where hardware comes in. To make use of big data and all its possibilities, scientists need new tools at their disposal. In this episode, host Jeremiah Owyang, alongside expert guests, traces the rise of large-scale computational resources used throughout the medical industry today.
Featured Guests:
–Daniel Ziemek, Vice President of Integrative Biology and Systems Immunology at Pfizer
–Enoch Huang, Head of Machine Learning and Computational Sciences at Pfizer
–Tor Aamodt, professor at the University of British Columbia
Season 4 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The intersection of biology and technology is revolutionizing drug discovery. In this episode, host Jeremiah Owyang and expert guests explore the crucial role of data in advancing medical science, from the serendipitous discoveries of the past to the cutting-edge techniques of today. They delve into the history of drug development, the rise of "omics," and the innovative single-cell sequencing that is transforming our understanding of the human body for the benefit of drug discovery. Today, scientists are using vast amounts of data to fuel artificial intelligence models, in the quest for new and better medicines.
Featured Guests:
– James Lowe, Research Fellow at the University of Exeter
– Kellie Kravarik, Associate Research Fellow and Cellular Genomics Group Leader for Systems Immunology at Pfizer
– Miguel Garcia-Sancho, Lecturer and Researcher at the University of Edinburgh
Season 4 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Artificial intelligence has the potential to help save millions of lives by accelerating the discovery and development of treatments for humanity’s toughest diseases. Those AI innovations come down to three key factors: data, hardware, and software. Science Will Win Season 4 takes listeners on a journey back in time to learn how each of these three elements got where it is today. Each episode features interviews with historians and cutting-edge researchers, framing these deep historical dives within modern advancements in medical technology. What challenges did science have to overcome to bring us where we are today, the midst of an AI revolution in medicine? Tune in to this new, four-part series, coming soon!
Season 4 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Throughout history, humans have coalesced around moonshot culture to achieve audacious goals—from eradicating smallpox, to sequencing the human genome, to landing a spacecraft on Mars. These feats of human ingenuity didn’t happen in a vacuum, they were born from intentional innovation, a “coalition of the willing,” and a vision to outdo yesterday. This fireside chat with Drew Panayiotou, CMO of Pfizer and Devon Still, ex-NFL player and founder of Still Strong Foundation, explores innovations in cancer, their personal experiences with family members needing healthcare treatment, and what it will take to achieve Pfizer's next big moonshot to outdo cancer and achieve its vision, a world where people with cancer live better and longer lives.
This episode was recorded live in Austin, TX on Monday March 11 as part of Pfizer’s takeover of the South by Southwest podcasting lounge.
The Let's Outdo Cancer Campaign aims to focus on advances in fighting against cancer. To learn more, visit letsoutdocancer.com.
Podcasting has exploded in the last 5 years, with every celebrity, brand, and influencer investing in audio. It’s estimated that 144MM people in the U.S. listen to a podcast monthly. With scale and an ability to build audience connections, podcasts have become effective at communicating complex information in a digestible way–making them perfect for sharing science-based stories. Many have heard the term "gene therapy," but how many know what it means? How do you explain the science behind artificial intelligence or designing the Mars Rover? Audio allows us to do this, while enhancing the impact of science communications. Join the Pfizer Podcast team, NASA, UT Austin, and Wonder Media Network as they share their audio expertise and accessible approach to scientific storytelling.
Featured experts:
- Shira Atkins, CRO & Co-Founder, Wonder Media Network
- Ellen Gerstein, Head Of Digital Communications, Pfizer Inc.
- Katie Konans, Audio Storytelling Lead, NASA
- Kristen Wynn, Program Manager, The University of Texas at Austin, Dell Medical School, Livestrong Cancer Institutes
This episode was recorded live in Austin, TX on Monday March 11 as part of Pfizer’s takeover of the South by Southwest podcasting lounge.
In a live taping of the Science Will Win podcast, Host and Artificial Intelligence Expert Jeremiah Owyang speaks to cutting-edge healthcare leaders about the impact that AI is having on the future of cancer. Thirty years ago, the thought of a world without cancer was nothing more than a dream. Similarly, AI was considered a technology that had yet to become reality. Today, we are reimagining a future where the AI revolution will help change the trajectory of cancer as we know it.
Featured experts:
- Edward Cox, Head & General Manager Of Digital Health & Medicines, Pfizer
- Julie Gerberding, CEO and President, Foundation for the National Institutes of Health
- Maimah Karmo, Founder & CEO, Tigerlily Foundation
This episode was recorded live in Austin, TX on Monday March 11 as part of Pfizer’s takeover of the South by Southwest podcasting lounge.
Is it possible to live in a world without antibiotic resistant bacteria? For the final episode of this season, we’re looking ahead to the future and getting a glimpse of a potential world in which we stay one step ahead of AMR, and what is helping us get there. Host Jeremiah Owyang and expert guests will talk about the education, surveillance, and policy efforts needed for success in the fight against antibiotic resistant bacteria. And we’ll explore how artificial intelligence can empower us in those efforts — and enable more effective, accessible, and equitable healthcare.
Featured Guests:
- Dame Sally Davies, UK Special Envoy for Antimicrobial Resistance
- Daniel Gallego, President of the European Kidney Patient Federation
- Ranjit Kumble, Vice President of Enterprise Data Science and Advanced Analytics, Pfizer
- Subha Madhavan, Vice President & Head of AI/ML, Quantitative & Digital Sciences, Global Biometrics & Data Management
- Jay Purdy, Vice President and Therapeutic Area Lead, Global Medical Affairs, Pfizer Antibacterial and Antifungal Programs
Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Artificial intelligence has the power to transform the way researchers study bacteria and develop new treatments – and we’re already seeing the benefits in healthcare. In part three, host Jeremiah Owyang and expert guests shed light on how AI expedites and enhances analyses, revolutionizing the search for new antibiotics. The benefits of AI extend to analyzing bacterial DNA, uncovering vulnerabilities, and potentially predicting bacterial evolution. This innovative technology aids scientists in pinpointing the most promising antibiotic candidates from a sea of possibilities and helps to streamline drug development.
Featured Guests:
- Adrian Egli, Director, Institute of Medical Microbiology, University of Zurich
- Lei Zhang, Executive Director of Medicinal Chemistry, Pfizer Medicine Design
- Marinka Zitnik, Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Co-founder, Therapeutics Data Commons
Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Artificial intelligence could be an essential tool in the fight against antibiotic resistant bacteria – and data is a key part of developing that tool. In part two of this four-part series, expert guests break down the mechanics behind artificial intelligence and machine learning. As host Jeremiah Owyang traces the evolution of these tools in healthcare, he highlights the crucial role of data for understanding the problem of antibiotic resistance.
Featured Guests:
- Adrian Egli, Director, Institute of Medical Microbiology, University of Zurich
- Ranjit Kumble, Vice President of Enterprise Data Science and Advanced Analytics, Pfizer
- Marinka Zitnik, Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Co-founder, Therapeutics Data Commons
Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Medicine’s struggle with antibiotic resistant bacteria is reaching a crisis point. In part one of this four-part series, host Jeremiah Owyang and expert guests delve into the world of antibiotics, exploring their history, the rise of antibiotic resistance, and the story of a patient whose life was forever changed by antibiotic-resistant bacteria. They break down the critical issues at stake and discuss the multifaceted solutions needed to combat this pressing crisis – including artificial intelligence.
Featured Guests:
- Adrian Egli, Director, Institute of Medical Microbiology, University of Zurich
- Jay Purdy, Vice President and Therapeutic Area Lead, Global Medical Affairs, Pfizer Antibacterial and Antifungal Programs
- Mary Lynne Van Poelgeest-Pomfret, President, World Federation of Incontinence and Pelvic Problems
Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
Since antibiotics were first discovered, bacteria have been evolving to outsmart them. But today, the latest science is rising up to meet the challenge. This season of Science Will Win is exploring how artificial intelligence (AI) can help the scientific community overcome one of the greatest challenges facing humanity: antimicrobial resistance. This season, we’ll hear from researchers, doctors, patients, patient advocates, computer scientists, and AI experts. All of them are on the cutting edge of the fight against antimicrobial resistance. Tune in to this new, four-part series, coming soon!
Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.
In part two of this series, Adam Rutherford and guests break down the next step in how potential breast cancer treatments move forward from the lab. What role do clinical trials play in the development of potential treatments? How are clinical trials developed? How can patients access clinical trials? And how are researchers and advocacy groups working to break down barriers in access to clinical trials?
Featured Guests:
- Laurie, Breast Cancer Clinical Trial Participant
- Dr. Edith Mitchell, Medical Oncologist, Thomas Jefferson University
- Julia Perkins Smith, Global Clinical Lead, Pfizer
- Jamil Rivers, CEO, Chrysalis Initiative
Additional Resources:
- pfizerclinicaltrials.com/oncology
- pfizerclinicaltrials.com
- pfizerestudiosclinicos.com
Oncologists have more innovative methods for treating breast cancer than ever before. In part one of this two-part series, Adam Rutherford and guests explore the hurdles and successes researchers face as they work to develop new, targeted therapies for breast cancer.
Featured Guests:
- Martha Carlson, Breast Cancer Advocate & Writer
- Dr. Edith Mitchell, Medical Oncologist, Thomas Jefferson University
- Jeff Settleman, Chief Scientific Officer, Pfizer Oncology
Host Adam Rutherford returns to explore breakthroughs in oncology, the study and treatment of cancer, and more specifically breast cancer. We’ll hear from the scientists tasked with developing new treatments, oncologists who lead clinical trials and treat patients, and the patients and patient advocates themselves. It’s a groundbreaking time for cancer research, with as many promising possibilities as there are challenges to overcome. Tune in to this new, two-part series, launching October 27, 2022!
In this special bonus episode, Adam Rutherford explores a different aspect of gene therapy - how do you actually make one? Expert guests discuss the highly complex task of scaling-up manufacturing from the small amounts needed for research, to creating batches big enough for clinical and commercial scale. And once that hurdle has been cleared, how do they address the additional challenge of storing and transporting the medicine at ultra-low temperatures?
Featuring guests:
Bert Bruce, Regional President, North America, Rare Disease, Pfizer
Bob Smith, Senior Vice President, Global Gene Therapy Business, Rare Disease, Pfizer
Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer
Gene therapy is at a pivotal moment. For eligible rare disease patients, the potential impact could be huge. So how can we support that potential to fruition and what will it mean if we do? In our season finale, host Adam Rutherford and guests take a peek into what a world with successful gene therapies could look like for patients, healthcare and society.
Featuring guests:
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Erik Paulsen, Chair, Institute for Gene Therapies
Karolina Hanslik, Former Senior Project Manager, EURORDIS
Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer
Paige Bischoff, Senior Vice President, Global Public Affairs, Alliance for Regenerative Medicine
Paolo Morgese, EU Director, Market Access, Alliance for Regenerative Medicine
Reda Guiha, IDM Regional President, Rare Disease, Pfizer
Simone Boselli, Director, Public Affairs, EURORDIS
Tomislav Sokol, Member of European Parliament
As with any new breakthrough medicine, entering the healthcare system comes with a host of obstacles and potential barriers. In this episode, Adam Rutherford and guests break down the big changes needed within the global healthcare ecosystem to ensure that, once approved, the therapies we’re researching now, like gene therapy, reach the patients who need them.
Featuring guests:
Bert Bruce, Regional President, North America, Rare Disease, Pfizer
Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Emily Crossley, Chief Executive Officer, Duchenne UK
Erik Paulsen, Chair, Institute for Gene Therapies
Karolina Hanslik, Senior Project Manager, EURORDIS
Katherine Beaverson, Senior Director and Patient Advocacy Lead, Rare Disease Research Unit, Pfizer
Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer
Suneet Varma, Global President, Rare Disease, Pfizer
Tomislav Sokol, Member of European Parliament
Gene therapy has come a long way to get where it is today but there is still much to learn and investigate. Host Adam Rutherford speaks to a line-up of experts about the vital role of clinical trials and the unique challenges facing gene therapy and rare disease patients.
Featuring guests:
Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer
Emily Crossley, Chief Executive Officer, Duchenne UK
Erik Paulsen, Chair, Institute for Gene Therapies
Professor John Rasko, Clinical Haematologist & Trial Investigator, University of Sydney
Simone Boselli, Director, Public Affairs, EURORDIS
Suneet Varma, Global President, Rare Disease, Pfizer
Gene therapy is a revolutionary field of science that has the potential to transform lives. It presents this big question; What if we could treat a disease at its root cause, rather than just the symptoms? On the first episode of Science Will Win, host Adam Rutherford takes us through the history, science, and significance of gene therapy.
Featuring guests:
Dirk Vander Mijnsbrugge, Vice President, Medical Affairs, Rare Diseases, Pfizer
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Laurence Woollard, Director, On The Pulse Consultancy
Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer
Science Will Win explores the fascinating science, policy, and humanity which is shaping the future of healthcare and transforming patients’ lives for the better.
Hosted by Adam Rutherford, geneticist and Honorary Fellow at University College London, our first miniseries takes listeners on a journey behind the science of gene therapy; the next generation of medicines bringing new possibilities for patients living with rare genetic diseases.
At a time when innovative science is achieving the seemingly impossible, we’ll look at gene therapy from every angle, speaking to scientists and experts on the forefront of medical research, as well as the patients and families who are holding new hope in the life-changing potential of gene therapy.